← back to search

Jason Whitt

University of Alabama at Birmingham · US
Area of research
Epidemiology · Pharmacology
Research interest
Research focused on Thyroid and Sulindac, with related work in Somatostatin receptor 2, Somatostatin receptor, Thyroid cancer. Notable publications include 'The Role of Notch3 in Cancer', 'A Novel Sulindac Derivative that Potently Suppresses Colon Tumor Cell Growth by Inhibiting cGMP Phosphodiesterase and β-Catenin Transcriptional Activity', and 'Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapy'.
h-index
citations
338
works
11
NIH funding
primary concept
email

Recent publications

Characterizing SSTR2 expression and modulation for targeted imaging and therapy in preclinical models of triple-negative breast cancer
Scientific Reports 2025cited by 4position: middledoi
PET Imaging of Differentiated Thyroid Cancer with TSHR-Targeted [<sup>89</sup>Zr]Zr-TR1402
Molecular Pharmaceutics 2024cited by 11position: middledoi
Thyroid-stimulating hormone receptor (TSHR) as a target for imaging differentiated thyroid cancer
Surgery 2023cited by 14position: middledoi
Voltage-Gated Sodium Channel NaV1.7 Inhibitors with Potent Anticancer Activities in Medullary Thyroid Cancer Cells
Cancers 2023cited by 13position: middledoi
Novel Non-Cyclooxygenase Inhibitory Derivative of Sulindac Inhibits Breast Cancer Cell Growth In Vitro and Reduces Mammary Tumorigenesis in Rats
Cancers 2023cited by 10position: middledoi
Somatostatin Receptor Type 2 and Thyroid-Stimulating Hormone Receptor Expression in Oncocytic Thyroid Neoplasms: Implications for Prognosis and Treatment
Modern Pathology 2023cited by 9position: middledoi
Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapy
Cancer Gene Therapy 2020cited by 42position: middledoi
Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment
Surgery 2019cited by 41position: middledoi
Pulmonary Carcinoid Surface Receptor Modulation Using Histone Deacetylase Inhibitors
Cancers 2019cited by 22position: middledoi
The Role of <i>Notch3</i> in Cancer
The Oncologist 2018cited by 90position: middledoi
A Novel Sulindac Derivative that Potently Suppresses Colon Tumor Cell Growth by Inhibiting cGMP Phosphodiesterase and β-Catenin Transcriptional Activity
Cancer Prevention Research 2012cited by 82position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Renata Jaskula‐Sztul · University of Alabama at Birmingham8 papers (2019–2025)Herbert Chen · Wayne State University7 papers (2018–2023)Rachael Guenter · University of Alabama at Birmingham5 papers (2019–2023)Suzanne E. Lapi · University of Alabama at Birmingham5 papers (2019–2025)Hailey Houson · University of Alabama at Birmingham3 papers (2023–2025)Margaret Liu · Beijing University of Technology3 papers (2019–2020)Grayson R. Gimblet · University of Alabama at Birmingham2 papers (2023–2024)Shannon E. Lynch · University of Alabama at Birmingham2 papers (2023–2025)Samuel Jang · Northwestern University2 papers (2018–2019)Anna G. Sorace · University of Alabama at Birmingham2 papers (2023–2025)Manuel Lora Gonzalez · University of Miami2 papers (2023–2023) · 2 papers (2023–2024)Tolulope A. Aweda · University of Alabama at Birmingham2 papers (2019–2019)Adam B. Keeton · Washburn University2 papers (2012–2023)Andrea Gillis · Total (France)2 papers (2023–2023)J. Bart Rose · University of Alabama at Birmingham2 papers (2018–2023)Carlos Gallegos · University of Alabama at Birmingham2 papers (2023–2025)Saad S. Kenderian · Mayo Clinic2 papers (2023–2024)Danilea M. Carmona Matos · University of Alabama at Birmingham2 papers (2019–2019)Gary A. Piazza · Auburn University2 papers (2012–2023)